On August 19, 2022, Public Joint-Stock Company "Human Stem Cells Institute" closed the transaction. The company amended the terms of the transaction. The company issued 7,645,451 shares at issue price of RUB 80 for a gross proceeds of RUB 611636080.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
59.54 RUB | +1.43% | -.--% | -.--% |
04-26 | Artgen Biotech PJSC Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Artgen Biotech PJSC Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 48.52M | |
+19.22% | 85.64B | |
-27.14% | 70.63B | |
+4.65% | 27.05B | |
-6.23% | 17.97B | |
+1.60% | 17.58B | |
+3.30% | 15.64B | |
+7.13% | 13.55B | |
+9.91% | 13.41B | |
+73.32% | 13.18B |
- Stock Market
- Equities
- ISKJ Stock
- News Human Stem Cells Institute
- Public Joint-Stock Company "Human Stem Cells Institute" announced that it has received RUB 611.63608 million in funding from PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy